Stanford Medicine researchers announced on September 17, 2026 that they built a virtual biotech company staffed by roughly 37,000 AI agents to accelerate drug discovery. Led by James Zou and Harrison Zhang, the AI system identified a biological pattern predicting clinical trial success and independently designed a lung cancer therapy that a major pharmaceutical company later validated, earning FDA breakthrough-therapy designation. The researchers say the system can analyze tens of thousands of past clinical trials to guide drug development far faster than conventional methods.
